跳到正文
原文
Nature 健康护理主题·· 8 天前AI 评分35

DTG为基础的抗逆转录病毒疗法在喀麦隆Bamenda地区HIV患者中的疗效观察

Effectiveness of a tenofovir/lamivudine/dolutegravir (TLD)-based regimen among people with HIV-1 attending the Bamenda Regional Hospital Treatment Centre, Cameroon: a retrospective observational study

AI 导读

一项回顾性观察研究评估了在喀麦隆Bamenda地区接受DTG为基础的抗逆转录病毒治疗的HIV患者病毒抑制情况,结果显示,治疗6个月和12个月时,95.5%和99.4%的患者病毒抑制率高,表明DTG在该地区疗效显著。研究未进行多变量调整,样本量较小,因此结果不适用于更广泛的人群。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Improving current and future antiretroviral treatment is crucial to ending AIDS by 2030. Treatment failure, drug toxicity and resistance remain major obstacles to durable viral suppression. In 2019, the World Health Organization (WHO) recommended a dolutegravir-based regimen (DTG) as preferred first- and second-line antiretroviral therapy to help address these challenges. However, data on its effectiveness among people with HIV-1 (PLHIV) receiving routine care remain scarce, particularly in Central Africa. This study evaluated virologic suppression among a cohort of adherent, comorbidity-free PLHIV receiving DTG at a regional treatment centre in Cameroon. This retrospective observational study reviewed the medical records of PLHIV aged above 18 years attending the Bamenda Regional Hospital HIV Treatment Centre, who had an adherence rate of at least 95% by pill count, had no recorded comorbidities, and were receiving dolutegravir as part of combination antiretroviral therapy (cART); 99.4% of participants were specifically on tenofovir/lamivudine/dolutegravir (TLD) and 0.6% on abacavir/lamivudine/dolutegravir. Both ART-naïve patients started on DTG-based first-line therapy and ART-experienced patients switched to a DTG-based regimen following the 2019 WHO recommendation were eligible. Eligible patients had initiated DTG-based cART between January 2020 and May 2021, early enough to have completed at least 12 months of follow-up before the close of the data-collection period in May 2022. The primary outcome was virologic suppression (< 1000 copies/mL) at 6 and 12 months, and the secondary outcome was 12-month DTG discontinuation due to a clinical switch to a non-DTG regimen. Because suppression was high (> 90%) with very few unsuppressed participants (7 at 6 months, 1 at 12 months), associations at 6 months were analyzed using crude risk ratios and Fisher’s exact tests. Multivariable adjustment was not possible, leaving the 6-month comparative analyses underpowered for small effect sizes, while formal 12-month statistical testing was omitted. Of 368 records screened, 157 participants met the eligibility criteria (105 treatment-naïve, 52 treatment-experienced) and had viral load data available at both 6 and 12 months. At 6 months, 150/157 participants (95.5%) were virologically suppressed; 7/157 (4.5%) were not. At 12 months, 156/157 participants (99.4%) were suppressed; 1/157 (0.6%) was not, and this participant was switched to a second-line regimen after confirmed virologic failure. No baseline factor examined sex, age, marital status, education, smoking, WHO clinical stage, treatment status, or HIV duration was significantly associated with 6-month suppression; given only 7 events, these null findings reflect limited statistical power rather than confirmed absence of association. Alcohol use at baseline was associated with a higher rate of 6-month suppression (risk ratio 1.14, 95% CI 1.02–1.28; Fisher’s exact p = 0.002); given the wide confidence interval, the small number of events, and the absence of adjustment for confounding, this finding should be treated as hypothesis-generating rather than confirmatory. By 12 months (week 48), the median weight change in the study population was + 2.0 kg (interquartile range [IQR] 0 to 4). In this adherent, comorbidity-free sub-population receiving routine HIV care in Cameroon, DTG-based cART was associated with high rates of virologic suppression at both 6 months (week 24) and 12 months (week 48), in both treatment-naïve and treatment-experienced participants. Because of the selective eligibility criteria, small sample, single-centre design and short follow-up, these findings should not be generalised to the broader population in routine HIV care, and do not by themselves establish comparative or causal effectiveness relative to other regimens; they add descriptive, real-world observations to the existing trial-based evidence for DTG-based regimens in a Central African setting.

Similar content being viewed by others

Abbreviations

3TC:

Lamivudine

ABC/3TC:

Abacavir/lamivudine

ART:

Antiretroviral therapy

ATV/r:

Ritonavir-boosted atazanavir

AZT/3TC:

Zidovudine/lamivudine

cART:

Combination antiretroviral therapy

CI:

Confidence interval

DTG:

Dolutegravir-based regimen

EAC:

Enhanced adherence counselling

PLHIV:

People living with HIV

RR:

Risk ratio

TDF:

Tenofovir disoproxil fumarate

VL:

Viral load

WHO:

World Health Organization

Acknowledgements

The authors thank the staff of the Bamenda Regional Hospital HIV Treatment Centre for their support in the realisation of this study.

Funding

This study was self-funded; the authors did not receive any specific funding for this work.

Author information

Authors and Affiliations

  1. Faculty of Health Sciences, University of Bamenda, Bamenda, Cameroon

    Rene Mih Tah, Ahmadou Musa Jingi & Martial Sonkoue Pianta

  2. University of Dschang, Dschang, Cameroon

    Jean Hubert Donfack

  3. Bamenda Regional Hospital, Bamenda, Cameroon

    Ahmadou Musa Jingi & Esther Neba Ngum

  4. Nkambe Regional Hospital Annex, Nkambe, Cameroon

    Rene Mih Tah

  5. Division of Operational Research in Health (DROS), Yaoundé, Cameroon

    Francis Ateba Ndongo & Anne-Cécile Zoung-Kanyi Bissek

  6. School of Medicine and Allied Health Sciences, University of The Gambia, Banjul, The Gambia

    Sheikh Omar Bittaye

  7. BioCoder MD, Bamenda, Cameroon

    Rene Mih Tah & Martial Sonkoue Pianta

Authors

  1. Rene Mih Tah
  2. Ahmadou Musa Jingi
  3. Martial Sonkoue Pianta
  4. Esther Neba Ngum
  5. Sheikh Omar Bittaye
  6. Francis Ateba Ndongo
  7. Jean Hubert Donfack
  8. Anne-Cécile Zoung-Kanyi Bissek

Corresponding authors

Correspondence to Rene Mih Tah or Sheikh Omar Bittaye.

Ethics declarations

Competing interests

The authors declare that they have no competing interests.

Ethics approval and consent to participate

Ethical approval for this study was obtained from the Institutional Review Board of the Faculty of Health Sciences, University of Bamenda (Project identification number: 2022/0411H/UBa/IRB). Administrative authorization to conduct the research was obtained from the North West Regional Delegation of Public Health, and permission to conduct the study at the HIV Treatment Centre was obtained from the Director of Bamenda Regional Hospital. As this was a retrospective review of existing medical records, the Institutional Review Board granted a waiver of individual informed consent. All methods were carried out in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tah, R.M., Jingi, A.M., Pianta, M.S. et al. Effectiveness of a tenofovir/lamivudine/dolutegravir (TLD)-based regimen among people with HIV-1 attending the Bamenda Regional Hospital Treatment Centre, Cameroon: a retrospective observational study. Sci Rep (2026). https://doi.org/10.1038/s41598-026-78550-x

Download citation

  • Received: 26 July 2026

  • Accepted: 27 October 2026

  • Published: 12 November 2026

  • DOI: https://doi.org/10.1038/s41598-026-78550-x

Keywords

来源:Nature 健康护理主题 · nature.com